PBPK Applications (MIFD) Using the Simcyp™ Simulator eBook 使用 Simcyp™ Simulator 的 PBPK 应用(MIFD) Explores strategies, regulatory validation, and solutions in small-molecule human Physiologically Based Pharmacokinetic modeling (PBPK).Simona Colucci2024 年 8 月 28 日
Certara’s Integrated, Compliant Clinical Data Solution From Trial to Regulatory Submission Guide Certara 从试验到监管提交的综合、合规临床数据解决方案 点击以下任一步骤,了解更多信息。Danielle Pillsbury2024 年 8 月 28 日
DMDG in vivo ADME one-day meeting 2024 Conference 2024 DMDG 体内药代动力学(ADME)一日会议 Danielle Pillsbury2024 年 8 月 27 日
《降低通胀法案》对生物类似药市场有何影响? 博客 《降低通胀法案》对生物类似药市场有何影响? The Inflation Reduction Act (IRA), one of the key legislative achievements the Biden-Harris administration, aims…Danielle Pillsbury2024 年 8 月 27 日
FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies Article FDA 对 Lykos 的拒绝延缓了迷幻疗法的发展 — 但并未阻止其步伐 Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…Danielle Pillsbury2024 年 8 月 26 日
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator Publication 预测涉及抑制作用的 CYP 介导的 DDIs:满足 Simcyp Simulator 系统鉴定要求的方法 The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…Danielle Pillsbury2024 年 8 月 26 日
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) Publication Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…Danielle Pillsbury2024 年 8 月 26 日
The Uncertain Path Forward for Psychedelic Medicine Article The Uncertain Path Forward for Psychedelic Medicine Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…Danielle Pillsbury2024 年 8 月 26 日